Bone marrow (BM) hematopoietic stem cells (HSCs) have long been known to possess the unique capacity for self-renewal and differentiation into hematopoietic and mesenchymal cell lineages (1) . That this plasticity extended to nonhematopoietic lineages such as hepatic oval cells, hepatocytes, cholangiocytes (1-3), skeletal muscle cells (4) , neurons (5) , epithelial cells of the lung, GI tract, and skin (6) is a relatively new observation, and has raised hopes that such cells could in the future be used for the regeneration and reconstitution of damaged organ tissue. This process of epithelial lineage regeneration appears to occur via a mechanism of spontaneous cell fusion or transdifferentiation. Emerging data in the field of cardiac regeneration suggest that incoming stem cells can also contribute to tissue repair by promoting neoangiogenesis and minimizing cardiomyocyte apoptosis (7) . Whatever the underlying mechanism by which the HSCs participate in tissue regeneration, it will still require the presence of HSCs to mobilize from the BM and reach their target organ. The aim of this review is to summarize current available information addressing the aspects of HSC mobilization and trafficking in response to liver injury.
ADULT STEM CELLS AND LIVER REGENERATION
While the liver is a mitotically quiescent organ in adult humans and animals (8) , hepatocytes have a remarkable capacity to meet the replacement demands during cellular loss (9, 10) . However, when either chronic/ extensive damage is inflicted on the liver or when hepatocyte proliferation is inhibited, a facultative cellular compartment of hepatic oval cells (HOCs), located within the smallest branches of the intrahepatic biliary tree is activated and leads to liver repair (10, 11) . More recently, several groups have demonstrated that BM-derived HSCs may contribute to liver repair (1) (2) (3) (12) (13) (14) . The contribution of HSCs to liver repair has varied, but is generally related to the presence and severity of liver injury. Thus, the restitutive response of the liver to different injuries has been proposed to include three levels of proliferating cells: 1) the hepatocyte, 2) the endogenous ductular progenitor cell or HOC, and 3) a pluripotent stem cell derived from circulating BM cells (9) .
Controversy has recently arisen as to whether HSCs contribute to the hepatocyte lineage in liver injury via transdifferentiation alone or by adopting the phenotype of hepatocytes after spontaneous cell fusion (15) . Recent reports in favor of the fusion hypothesis have demonstrated that adult cells can adopt the phenotype of other cell lines by fusing with embryonal stem cells (16, 17) as well as BM-derived hepatocytes generated by in vivo cell fusion (18) . In support of transdifferentiation, several groups have demonstrated that HSCs can differentiate into hepatocytes (19, 20) and pancreatic endocrine cells (21) without any evidence of cell fusion. The mechanism of HSC hepatic regeneration remains unresolved; clearly, any future stem cell research will have to distinguish HSC transdifferentiation from fusion events. Whatever the mechanism of hepatic regeneration is, the trafficking of HSCs to the liver may play an important component of the reparative process in liver injury.
The contribution of HSCs to hepatocyte lineages in rodents and humans remains a controversial area with data both supporting (1-3, 13, 14, 22) and rebutting (23) (24) (25) findings. This may in part reflect the types of cells used, the injury models used, and the methods used to detect stem cell progeny. Nevertheless a therapeutic role of HSCs in liver injury has been described in rodents (13, 26) , albeit with varying contributions of transdifferentiation and fusion. In other models, particularly in humans, the contribution that HSCs make to liver repair by transdifferentiation is lower, on the order of 0.011-20% (2, 3, 6, 27-29). To improve on this level of contribution will require greater understanding of the mechanisms by which stem cells mobilize from the BM and home to injured organs. There remains a pressing need for further studies to confirm or refute the claims that stem cells can lead to improved liver repair and hence survival in either a rodent or human setting.
Murine and human studies have shown that the chemokine stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, are involved in recruiting inflammatory cells into injured livers as well as inducing proliferation of endogenous HOCs (30, 31) . SDF-1/CXCR4 interactions participate in the mobilization of HSCs from BM and have been implicated in the migration of human HSCs to the liver during injury (32, 33) . Other factors have been implicated in the regulation of hepatic migration of HSCs, including interleukin-8 (IL-8), hepatocyte growth factor (HGF), and matrix metalloproteinases (MMPs).
ADULT STEM CELL MOBILIZATION AND RECRUITMENT IN LIVER INJURY
Human studies have demonstrated increased levels of circulating HSCs in response to a systemic injury such as acute sickle cell crisis and surgical trauma (34, 35) . A recent study by De Silvestro et al. demonstrated that peripheral blood HSC levels were elevated after extensive liver resection (36) . Our group has demonstrated that in patients with alcoholic hepatitis there is an increase in circulating HSCs when compared with normal controls (37) . The extent to which these peripheral blood HSCs are mobilized into the circulation of patients with liver injury and contribute to liver repair remains uncertain and is under investigation.
Release of HSC from the bone marrow
In the adult BM, the release of HSCs into the peripheral circulation is regulated in part by the CXC chemokine SDF-1 and its receptor CXCR4 (32, 33, 38, 39) . SDF-1 is a potent chemoattractant for HSCs and is produced by various BM stromal cell types and epithelial cells in a broad range of normal tissues, including the liver (40 -46) (see Table 1 ). It plays a major role in the homing, migration, proliferation, differentiation, and survival of many cell types including human and murine hematopoietic stem/progenitor cells (32, 33, 38, 39, (47) (48) (49) (50) . Knockout mice deficient in SDF-1 exhibit disturbed hematopoiesis and knockout mice deficient in the CXCR4 receptor die in utero (51, 52) , underlining their importance.
SDF-1 is highly conserved between mice and humans (53, 54) , mediating its effect through the CXCR4 receptor that is expressed on CD34
ϩ HSCs, mononuclear leukocytes, and a variety of stromal cells (53) . CXCR4 is a G-protein-coupled, 7-transmembrane receptor and is the only known receptor for SDF-1 (55) . The interaction between SDF-1 and CXCR4 has been demonstrated to trigger multiple intracellular signals, including calcium mobilization and phosphorylation of adhesion components such as extracellular signal-regulated kinases 1 and 2 (ERK-1 and -2), proline-rich tyrosine kinase 2 (Pyk-2), focal adhesion kinase (FAK), and protein kinase C (PKC) (56, 57) In the adult BM, release of HSCs into the peripheral circulation is controlled in part by a concentration gradient of SDF-1 established within the BM microenvironment (39, 58, 59) . Reduction of BM SDF-1 levels has been shown to result in release of HSC into the peripheral circulation, an effect mediated partly by granulocyte colonystimulating factor (G-CSF), which induces the release and proliferation of neutrophil proteases such as elastase, cathepsin G, and MMPs (33) . Increased expression of SDF-1 in the peripheral circulation facilitates further mobilization of HSCs down a concentration gradient (60) .
Several reports demonstrate increased circulating plasma levels of SDF-1 in autoimmune and viral diseases, in conjunction with increased expression of SDF-1 in the parenchyma of rejecting liver transplants and viral/autoimmune liver diseases (31, 61) . These observations have been reported in murine liver injury models (12, 30) , suggesting that liver injury may, by the 
into the circulation and then into the liver (12, 31) (see Fig. 1A-C) .
The mechanism by which SDF-1 influences HSC mobilization is unclear, although it is thought to involve specific changes to the adhesion of progenitor cells to the BM microenvironment via the modulation of adhesion molecules such as the integrin-dependent very late antigen-4 (VLA-4) (62). In vitro there is an increased trans-endothelial migration of human progenitor cells toward a gradient of SDF-1 (48, 63) , and SDF-1 has been shown to promote the survival of circulating CD34
ϩ HSCs by counteracting apoptosis via the activation of the phosphotidyl inositol 3 kinase (PI3-K)/Akt pathway (64) .
It has been speculated that the release of proteolytic enzymes and chemokines from injured liver into the circulation could also facilitate mobilization and recruitment of HSCs (12) . Studies with G-CSF have revealed neutrophil proteolytic enzymes such as elastase, cathepsin G, and MMPs, including MMP-2 and MMP-9, result in the proteolytic degradation of SDF-1 in the BM, thus facilitating the release of stem cells (33, 65) . MMPs degrade extracellular matrix proteins and are known to play important roles in tissue inflammation, tumor growth, and organ remodeling (66, 67) . MMPs are secreted as zymogens (pro-MMPs) that are activated by a variety of proteinases and inhibited by tissue inhibitors of metalloproteinases (TIMPs) and ␣2-macroglobulin (66). In humans, MMP-9 is produced in a wide variety of cells types such as neutrophils, progenitor cells, endothelial cells, fibroblasts, connective tissue cells, tumor cells, and parenchymal cells, including the liver (66, 68) . Human and animal studies have demonstrated that MMP-9 promotes the release of progenitor cells from the BM into the circulation by 1) inducing the release of soluble kit-ligand (sKitL) from BM stromal cells, which accelerates the proliferation and migration of HSCs, 2) cleaving the interaction of adhesion molecules VLA-4/vascular cell adhesion molecule-1 (VCAM-1) between stromal cells and HSCs in the BM, and 3) enhancing the SDF-1 induced migration potential of HSCs across the subendothelial basement membrane (38, 69 -71) . In addition, MMP-9-induced recruitment of HSCs may occur via other mechanisms such as the shedding of membrane-bound stem cell factor (SCF) and the secretion of MMP-9 by progenitor cells in response to SDF-1 stimulation (70, 71) . MMP-9 has been demonstrated to have an active involvement in liver remodeling in cirrhosis and inflammation as well as regulating hepatocyte regeneration after partial hepatectomy (72) (73) (74) .
Human studies have demonstrated elevated serum and plasma MMP-9 levels in various types of liver injury including acute allograft rejection (75) , ischemic reperfusion injury (76, 77) , chronic viral hepatitis (78, 79) , and alcoholic liver cirrhosis (80) , suggesting there is a correlation between disease severity/progression and MMP-9 expression. In these studies, 70 -80% of the serum and plasma MMP-9 measured, appeared in the active complex form and could be detected in serum samples from as early as 30 min and Ͼ1 wk after an acute injury process. In chronic liver diseases such as alcoholic cirrhosis, persistently elevated plasma activities of MMP-9 have been demonstrated, suggesting its expression reflects a process of ongoing extracellular matrix remodeling (80) . Carbon tetrachloride (CCl4) -induced liver injury studies in rats and NOD/SCID mice (in which bone marrow cells were seen to transdifferentiate into hepatocytes) demonstrated an increased expression and activation of MMP-9 in the liver, suggesting that this factor could potentially be involved in the stress-induced recruitment of HSCs from the BM to the injured liver (12, 81) . A recent study by Hanumegowda et al. (82) has demonstrated an increased activation of MMP-9 in the livers of rats with monocrotaline-induced liver injury (which inhibits hepatocyte proliferation and promotes an HOC response). This increase in MMP-9 activity was produced from either the endothelial cells or from an activation or influx of inflammatory cells into the injured hepatic parenchyma (82) . In a study by Watanabe et al, mice were injected with anti-Fas antibody (Jo2) to induce an acute hepatitis, demonstrating that MMP-9 expression in the circulation was elevated and accompanied by the recruitment of HSCs from the BM into the circulation (83) .
Interactions between MMP-9 and other chemokines such as IL-8 have been demonstrated in mobilization studies whereby MMP-9 is rapidly induced in neutrophils after exposure to IL-8 and resulting in the release of HSCs into the peripheral circulation (84 -87) (see Fig. 1B ). Elevated IL-8 levels have been demonstrated in the circulation and hepatic parenchyma of many human liver conditions including alcoholic hepatitis, viral hepatitis, chronic alcoholic liver disease, and acute graft-vs.-host disease after liver transplantation (88 -92) . Thus IL-8, a known neutrophil chemoattractant in liver disease, also has the potential to induce the release of HSCs into the peripheral circulation via an indirect mechanism requiring the activation of circulating neutrophils and the release of MMP-9 (86). (Fig. 1C) Kollet et al. have recently demonstrated the key role that SDF-1/CXCR4-mediated signaling plays in the migration of human progenitors to the murine liver. Neutralization of the CXCR4 receptor with an anti-CXCR4 antibody significantly inhibited the homing of human cord blood or mobilized peripheral blood CD34 ϩ stem cells to the liver of irradiated NOD/SCID mice (12) . Furthermore, injection of human SDF-1 into the murine liver parenchyma further enhanced the hepatic migration of human stem cells. SDF-1 expression has been reported in a variety of liver and nonliver conditions such as liver allograft rejection (61), viral and autoimmune liver diseases (12, 31) , ischemic brain injury (93) , myocardial infarction (94), inflammatory skin conditions (44) , and BM injury induced by total body irradiation or chemotherapy (95) . It is unclear whether this expression is an attempt to recruit inflammatory cells or HSCs toward the damaged organ or is indeed entirely unrelated.
Hepatic recruitment of HSCs in liver injury
SDF-1 expression in rejecting liver transplants and viral/autoimmune liver diseases was seen to be confined to the biliary epithelium and other nonparenchymal cells, thus promoting the retention of CXCR4 ϩ lymphocytes and possibly HSCs in the portal tracts (12, 31, 61) . Hatch et al. (30) were able to demonstrate that SDF-1 protein was up-regulated in the membrane fraction of the whole liver lysates. Notably, however, this was only the case in animals that had undergone HOC regeneration models [partial hepatectomy (PH) and 2-acetylaminofluorene (2-AAF) or 2-AAF and CCl4]. Animals that had undergone non-oval cell regeneration models of PH, CCl4 alone, and 2-AAF alone did not produce SDF-1 protein. Immunohistochemistry on the oval cell regeneration model liver sections revealed increased expression of SDF-1 in the hepatocytes adjacent to the proliferating oval cells and positive CXCR4 staining on these oval cells. These data argue for the defined production of SDF-1 in forms of liver injury that may be attempting to recruit HSCs to the reparative process.
The cytokine HGF, which is produced in the nonparenchymal perisinusoidal cells of the liver and induces hepatocyte proliferation, may also be involved in the migration and differentiation of HSC into the injured liver (12, 96) . Increased expression of HGF has been demonstrated in CCl4-induced liver injury and in rodent HOC regeneration models, suggesting it is involved in stem cell proliferation, migration, and differentiation (22, 97) . Kollet et al. recently demonstrated that after liver injury, levels of HGF were increased and contributed to the recruitment of human CD34
ϩ stem cells to the injured liver (12) by increasing the motility of human progenitors and in synergy with SCF potentiated both CXCR4-and SDF-1-induced directional migration.
CONCLUSIONS
Many concepts regarding stem cell migration and plasticity come from studies of multipotent hematopoietic stem cells and the molecular pathways of hematopoiesis (98) . There is now increasing evidence to suggest that liver injury induces the expression and secretion of signaling mediators such as SDF-1, IL-8, MMPs, HGF, and SCF, which facilitate the homing and engraftment of HSCs to the liver (12, 30, 31) . Factors regulating long-term engraftment and differentiation of HSCs into hepatocytes are yet to be defined, although chemokines, adhesion molecules, and extracellular matrix factors would appear to have an important role to play. A better understanding of the factors regulating HSC homing, subsequent engraftment into the liver, and finally differentiation into hepatocytes are essential if the potential therapeutic manipulation of HSCs to treat liver disease is to be realized. 
